Aarti Drugs Limited

Aarti Drugs Limited

502.85
INR
+1.05
(+0.21%)
25.06EPS
17.17P/E
39.30BMarket Cap
Jan 27Next Earn

Q4 FY2026 · Earnings Call TranscriptMay 18, 2026

Operator

Ladies and gentlemen, good day and welcome to Aarti Drugs Limited Q4 FY '26 earnings conference call. This conference call may contain forward-looking statements about the company which are based on the beliefs, opinions, and expectations of the company as on date of this call.

These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing star, then zero on your touch-tone phone. Please note that this conference is being recorded.

I now hand the conference over to Mr. Adhish Patil, COO and CFO from Aarti Drugs Limited.

Thank you, and over to you, Mr. Patil.

Adhish Patil

Thank you. A very good morning and welcome to the Q4 and FY '26 earnings conference call of Aarti Drugs Limited.

Joining me today are Mr. Harshit Savla, Joint Managing Director; Mr.

Harit Shah, Whole-time Director; Mr. Vishwa Savla, Managing Director of Pinnacle Life Science Private Limited; along with our Investor Relations Advisors, SGA.

We trust that you have had the opportunity to review our financial results and investor presentation for the quarter and full year ended 31st March 2026, which have been uploaded with the stock exchanges and are also available on our website. Let me start by outlining the key business and financial highlights for the period.

FY '26 was an important execution year for Aarti Drugs as we moved from the investment phase into the operational scale-up phase. From a broader industry perspective, FY '26 remained challenging due to multiple macroeconomic and geopolitical uncertainties, including global trade disruptions, trade tariffs, and GST changes, and pricing volatility.

Towards the end of FY '26, by elevated input cost, crude and gas-based raw material supply chain constraints due to the West Asia war. During the quarter, freight, packaging, utility, and energy-related costs also remained elevated, while availability of certain key raw materials remained inconsistent at various points.

Despite a challenging operating environment for the industry, the business exited the year on a much stronger footing with a sharp sequential recovery in Q4 FY '26. Operational initiatives such as process optimization, alternate sourcing strategies, energy efficiency measures, and tighter planning helped us mitigate part of these pressures and ensure continuity of operations.

Now we'll talk about consolidated financial highlights. Q4 FY '26 revenue stood at ₹721.1 crore as compared to ₹678.6 crores in Q4 FY '25 and ₹602.9 crores in Q3 FY '26, reflecting a growth of 6% year-on-year and 20% quarter-on-quarter, respectively.

EBITDA stood at ₹96.6 crore versus ₹95.2 crores in Q4 FY '25 and ₹56.3 crores in Q3 FY '25, indicating flattish year-on-year growth and a growth of around 72% on quarter-on-quarter basis. EBITDA margin stood at 13.4%.

PAT stood at ₹55.3 crore as compared to ₹62.8 crore in Q4 FY '25 and ₹40.5 crore in Q3 FY '26, a degrowth of 12% year-on-year and up to 36% Q-on-Q increase. PAT margin translated to 7.7% for Q4 FY '26.

With respect to the standalone business highlights for Q4 FY '26, revenue stood at ₹631.7 crores versus ₹623 crores in Q4 FY '25. Standalone business contributed around 88% to the consolidated revenue.

63% of the standalone revenue came from the domestic market and 37% from the export market. Domestic revenue grew by 7% year-on-year, whereas export revenue declined by 7% year-on-year.

Within the API business, the antibiotic therapeutic category contributed around 37.8%, antiprotozoal around 19.6%, anti-inflammatory around 11.9%, antidiabetic 15%, antifungal around 10%, and the rest contributed around 5.7% to the total API sales. Now let's talk about formulation segment highlights.

Revenue from formulations stood at ₹91.3 crores compared to ₹64.8 crores in Q4 FY '25, up by 41% year-on-year basis. Exports contributed 69% to this revenue.

For FY '26, formulations revenue was ₹330.5 crore compared to ₹284.9 crore in FY '25, up by 16%, with exports accounting for 65% of total formulations sales. Volume growth in the domestic market remained healthy, and we witnessed momentum in select non-antibiotic and export-led products.

Export markets, especially formulations, emerged as a key growth driver, supporting overall business stability. As highlighted in slide 10 of our investor presentation, Aarti Drugs has consistently delivered positive volume growth over last five years despite sharp pricing corrections across the industry.

While this pricing pressure impacted realizations and top-line growth across the sector, our ability to sustain volumes and maintain customer relationships reflects our trust with the clients. Encouragingly, pricing trends started stabilizing from September 2025 onwards, and this recovery strengthened further during Q4 FY '26, supported by increasing crude prices, and is expected to improve realizations in the short run.

A key pillar of our performance during the quarter was the continued ramp-up of our new manufacturing facility, most notably our backward integration plant for methylamines at Saykha. The facility ramped up meaningfully and was tested at higher utilization levels, where operational performance remained encouraging.

While the initial ramp-up phase witnessed temporary headwinds, the facility achieved a production rate of nearly 1,000 tons per month during the month of March 2026. We expect to make further progress on utilization ramp-up during FY '27.

Over time, the project is expected to significantly reduce dependence on externally sourced inputs and improve self-sufficiency for the metformin portfolio, thereby supporting margin improvement and operating leverage. Another important structural improvement during FY '26 was the increasing contribution from regulated and export-oriented markets.

Exports contribution increased from 35% in FY '25 to 38% in FY '26, from which regulated market contribution also grew to 73% compared to 66% [unclear]. This gradual shift towards regulated markets and higher value products indicates the company's ability to meet stringent regulatory norms and adhere to international quality standards.

Overall, while FY '26 remains a transition year operationally, the business ended the year with significantly improved momentum, supported by stabilizing pricing trends, stronger exports, improving product mix, and a gradual ramp-up across newly commissioned facilities. With that, I would like to now open the floor for questions.

Thank you.

Operator

Thank you. We will now begin the question-and-answer session.

Anyone who wishes to ask a question may press star and one on your touch-tone telephone. If you wish to remove yourself from the question queue, you may press star and two.

Participants are requested to use handsets while asking a question. Ladies and gentlemen, we will wait for a moment while the question queue assembles.

The first question comes from the line of Nilesh Ghuge with HDFC Securities. Please go ahead.

Mr. Ghuge, please go ahead with your question.

Mr. Ghuge, please unmute yourself and go ahead with your question.

Since there is no reply from the line of Mr. Ghuge, we will move to the next participant.

That is Mr. Shashank Koil from Umara Capital.

Please go ahead.

Shashank Koil

Hello. Yes, thank you so much for the opportunity, and these were very good numbers.

The first question is, how is the methylamines plant right,

Operator

the

Shashank Koil

ramping up? What utilization has it reached, and what do you expect over the next two years?

Methylamines plant.

Adhish Patil

Are you talking about methylamines plant in Saykha?

Shashank Koil

Yeah.

Adhish Patil

Okay. Yeah.

We just started that plant in the month of September. December quarter was the first quarter where we showed a utilization of around 29% roughly.

Then in the March quarter, we were able to achieve 40%, a little upwards of 40%. We fell slight short of our target of 45-50%, mainly because of ammonia-based raw materials in that plant because of the West Asia war.

Going forward, we are expecting that in June quarter, we should easily cross around 55-60% of utilization for that plant. Within a year's time, we believe that we should be operating upwards of 70% utilization of the methylamines plants.

Shashank Koil

Okay. My next question is on the salicylic acid.

What was your profitability at an EBITDA level last quarter, and what sort of margin and revenue profile can it reach over the next few quarters assuming there is no change in duty structure?

Adhish Patil

Yeah. The salicylic acid still remains a laggard.

As we were talking in last quarter that we were expecting one equipment. The delivery was expected in late April.

We took a call because we were making variable losses in salicylic acid because we were not able to recover and reduce the raw material cost because of lack of that equipment. We took a call to shut down that production, and once all the equipments are operational, once we test it, once the variable costs are in check, and then we will restart the production of salicylic acid.

That is the latest update of salicylic acid. We do expect and hope that we will improve and very quickly, we should start with forward integration of salicylic acid as well because that plant is already commissioned.

Now we'll need to do piloting and scale-up of the derivatives plant.

Shashank Koil

Okay. Thank you so much.

That's all from my end. Thank you.

Adhish Patil

Thank you.

Operator

Thank you. A reminder to all the participants that you may press star and one to ask a question.

Next question comes from the line of Dhwanil Desai with Turtle Capital. Please go ahead.

Dhwanil Desai

Hi. Good morning, Adhish.

My first question is your opening comments mentioned that Q4 you ended on a strong note, and realizations were also kind of stabilizing, and because of this West Asia conflict, that there is some improvement. Given that we have large capacity which is already in place, and the negative rate variances behind us, should we expect 10-12% volume growth and maybe some 4-5% positive rate variance because of the regulated market contribution going up and overall incremental pricing that we are getting because of the higher crude?

Adhish Patil

Yeah. The current situation is such that the API prices remained elevated because of West Asia war.

If this persists for longer, then definitely there will be a lot more positive rate variances. Nevertheless, we will always strive for achieving a volume growth of 8-10%, as you said, we also have already built up capacities from 2 Greenfield expansions.

Achieving that kind of volume growth would be fairly easy. Realizations, it definitely will be positive.

The longer the war stretches, the positive variance would be more.

Dhwanil Desai

Okay. One follow-up on this, Adhish.

We are talking about 8-10% volume growth, but if you look at the last two, three years, we have put up so much of CapEx, and the new capacity is coming on stream. With that, if we are talking about 8-10% volume growth, does it mean the existing base business, there we are not expecting much of a volume growth, because that sounds slightly on the lower end, right, with the new capacity on so many new products, salicylic acid, methylamine, SpecChem?

With all that, why at a company level, we will only grow at 8-10% volume growth?

Adhish Patil

Yeah. The internal target would always be in the range of 10-15% growth.

Right now, what is happening that, with the very high pricing in the antibiotic segment, last time what we observed was the domestic demand had gone down. That is what we fear.

If the crude prices remain elevated very high, then the older generation molecules, which are already being sold at a very cheaper rate in the Indian market, and there is some kind of price regulation for the formulation players. When the API become very expensive, typically the demand of those products goes down, and that is what we had observed during Russia-Ukraine War as well in 2023.

That is the only challenge what we think we can face for antibiotic category in the domestic market if the prices are too high. If the prices are moderate, then it won't affect the demand, but if they're too high, the crude remains too high, then probably that might be the reason.

Dhwanil Desai

Okay. Second question on the gross margin side of it.

I think there is some improvement standalone basis on a gross margin. How should we look at gross margin given that realizations are up, but input costs also is up?

At the same time, regulated thing is kind of scaling up, rupee has depreciated, import, export. Multiple factors kind of playing into this.

Are we expecting any delta in gross margin for the coming year, given all this?

Adhish Patil

The thing is, we don't expect much movement in gross margins as such. Anyways, in Q4, we did fairly good in terms of gross margins.

What we would like is we would like to maintain this kind of gross margins. In Q4, what happened, our manufacturing costs were little higher, but they can be reduced by a percent or so, which can lead to improvement in EBITDA margin.

There are few factors. Like the more regulated sales what we are targeting, that will help in increasing the gross margins.

On the flip side, if the prices of the APIs goes too high because of the raw material prices, typically what happens is that to maintain certain level of absolute gross profit per kg of a product, the margin tends to lower in terms of gross margins. You got my point?

Dhwanil Desai

For example,

Adhish Patil

if we are making Yeah. 36%

Dhwanil Desai

Right. I got your point.

That absolute number can go up, but percentage, it will look on the lower side. Denominator.

Right. Got it.

My point is that, in percentage terms, it may not go up much, maybe stabilize or slightly lower. In absolute terms, if the delta is higher, does it mean that the flow-through to the EBITDA will be significantly better and hence EBITDA margin?

Adhish Patil

It can. There is a possibility.

Dhwanil Desai

Okay. Got it.

Last question is on the formulation side. We did very well on the formulation side.

What are the contributing factors? I think our oncology thing is still, the dossiers are still in the approval stage, it will take some time.

What is driving this growth? Going forward, this kind of a run rate is possible to maintain?

How should we look at it?

Adhish Patil

Yeah. Vishwa, would you like to answer this question?

Vishwa Savla

Yes. Sure.

As you rightly said, our oncology plant is still pre-revenue. The current growth is coming from our direct exports in the non-oncology portfolio.

Since we have a growing list of products that we are getting approvals across regulated markets, that is the business that is growing quickly, and that is why our export business is also increasing, which is leading to better margins as well. Going ahead too, we are expecting a good number of approvals and market extensions, which will help us keep increasing the export business at a similar pace.

Dhwanil Desai

This ₹90 crores run rate that we got, I think that number is something which is possible to maintain in FY '27, is that a fair way to look at it?

Vishwa Savla

That's a fair assumption. Correct.

Dhwanil Desai

Got it. Thanks.

That's it, and all the best.

Adhish Patil

Thank you.

Operator

Thank you. A reminder to all the participants that you may press star and one to ask a question.

Next question comes from the line of Jain Jain with JJ Capital. Please go ahead.

Hi, sir. Sir, I have a couple of questions.

Firstly, sir, regulated market contribution increased materially in FY '26, as you have highlighted. Sir, what are the key geographies leading to this improvement, and which products?

Adhish Patil

Yeah. I would like to highlight that this would be mainly Latin American markets.

Still European market and US market would be our target market for more and more regulated sales going forward. This hasn't seen an uptick yet, but it looks very promising because we are seeing lot of business development activities are going on with this client.

Lot of approvals are coming in for the facility as well as for the product. Within a year's time, at least towards the end of the year, we should start seeing some kind of flow in the regulated markets from our recently reapproved US FDA plant as well as other products.

In fact, in lot of our other dedicated plants as well, we have taken CEPs, which are the European approvals for antifungal products. Then we have got for anti-inflammatory as well.

Yeah. Are you asking anything else?

Yeah. Sir, the second is, what is the status update on timeline for key US FDA approvals and DMF filings across APIs and formulations?

Adhish Patil

For APIs?

Yeah.

Adhish Patil

For API, we got the approval for US FDA already last year, the plant approval. There are few antibiotic, anti-inflammatory, and few other therapies where we are actively marketing those products in the US market, and the flows will start within 12 to 18 months, is what we expect.

Then we have oncology as well for the US markets, where we are filing dossiers in formulation business.

Yeah. Lastly, also, can you please highlight the status of anti-dumping duty for allied products?

Adhish Patil

Can you repeat the question? I was not able to hear.

Lastly,

can you please highlight the status of anti-dumping duty for allied products?

Adhish Patil

Okay. Yeah.

What I could make of your question was you're asking about anti-dumping.

Regarding the anti-dumping duties, yes,

Adhish Patil

sir.

For the allied products.

Adhish Patil

Yeah. We are in the process of application for salicylic acid.

That is ongoing. As we speak now, the application is done, and we are going ahead with the various stages of that anti-dumping duty application.

Okay. Thanks a lot.

Thank you.

Adhish Patil

Thank you.

Operator

Thank you. A reminder to all the participants that you may press star and one to ask a question.

Next question comes from the line of Sajal Kapoor with Antifragile Thinking. Please go ahead.

Sajal Kapoor

Hi, Adhish. I joined the call a little late, I missed your opening remarks.

I'm sorry about that. Maybe my questions are a little different.

Firstly, what challenges in the amines ramp-up were kind of external and outside management control?

Adhish Patil

Sorry to interrupt you. There is a bit of disturbance from one of the line.

Operator

Just checking. Please give me a moment.

Speakers, the disturbance is coming from the line of Mr. Harshit Savla.

Please go ahead.

Sajal Kapoor

Okay. Yeah.

Thank you. Hi, Adhish.

What challenges in the Saykha ramp-up were kind of outside your control or were external? It could be ammonia shortage or raw material volatility or some other factors.

Which challenges were kind of internal execution issues where we or the company underestimated timelines, utilization curves, or operational complexity? Because greenfield plants are always challenging in terms of scaling up, right?

What often works on the design doesn't actually show up in the

Adhish Patil

real

Sajal Kapoor

production, real-world challenges. If you can split your response in something which was internal and could have been better managed and the factors that were outside your control and how we should look at in this particular amines greenfield going forward FY '27, this fiscal.

Thank you. Yeah.

Yeah. We speak

Adhish Patil

we spoke about the Saykha plant little earlier. We said that we started this plant, the first quarter was December quarter where the the plant was operational at at a full scale.

Just give me a moment. Earlier we were just able to hit the run rate of around a little less than 30% utilization in the month of in in the quarter of December.

Whereas, in the quarter of March, in spite of the fact that there were slight raw material shortages, we were able to achieve utilization upwards of 40%, slightly above 40%. What we are seeing as far as first half of Q1 is concerned, we are already we have already utilized the plant around 60%, the Saykha plant.

The methylamines scale-up is going pretty well. We did not face much issues in this plant like the Tarapur facility of salicylic acid.

Whereas the the better utilization of this plant will go slightly depends on our expansion plans of metformin itself, which are also on its way as we speak right now. We are expanding metformin production as well.

More the metformin production, more will be the utilization of the Saykha plant. As far as internal problems are concerned, there are very minor issues at at the drying of one of the derivatives of methylamines, but we are not worried about that as of now.

Because still we are able to increase our utilization and probably within, 3, 4 months, the the the real profitability of Saykha plant will start showing in our results.

Sajal Kapoor

Sure. No, that's helpful, Adhish.

In terms of the metformin, how much of the value chain do we now control? Because, see, the state of India as a whole in metformin specially was the fact that no one, absolutely no one was backward integrated, right?

Everyone was dependent on China. How is the situation on the ground today as far as Aarti Drugs are concerned for metformin?

Yeah.

Adhish Patil

Metformin, there are two main intermediates. One is sourced from China and Europe, and the other one is indigenous, mostly domestically.

The DCDA, which is imported, there are a lot of players in that. Not much margins to be made in that product as of now.

Plus it has a explosive chemistry, hazardous chemistry as well in terms of manufacturing. Whereas the indigenous intermediate was concerned, for Met, there, I believe, now we are the only ones, as of today, with a backward integration facility.

That puts us in a very good position. We were already very cost competitive in metformin because we were clearly leaders means with handsome majority when it comes to selling metformin in semi-regulated or I won't call unregulated because none of the API markets are unregulated as of now.

I would say other than the highly regulated markets, the ROW market, we were absolute leaders in metformin where cost of production is very important. With the advent of this backward integration, our cost will further go down.

Another important update on metformin is that we have already filed a DMF with US for metformin. Now slowly once we ramp up the capacity, we would like to invite FDA to inspect our dedicated metformin facility.

That would be the next stage for metformin. We already have the European approval, but what we feel is that US approval is the key even for selling the metformin to European markets.

Sajal Kapoor

Okay. That's helpful.

Given our backward integration projects are now ramping up, is it fair to expect that every year should show YoY, if not quarter-over-quarter, improvement in terms of the margins? Because, see, the economics of the business are simple, the fixed costs are fixed, right?

As the utilization improves and as long as the realizations are not suffering big time, right, and there is also anti-involution talk coming from China. Putting all that into perspective, is it fair to expect at least 100 to 200 basis points EBITDA improvement in FY '27?

Adhish Patil

Yes. We can expect that in terms of gross contribution.

100 At least 100 basis points, we can definitely target.

Sajal Kapoor

When do we see us going back to the sunny days scenario? In 2015, '16, '17 era, we were having 16% operating margins pretty consistently.

Adhish Patil

Right.

Sajal Kapoor

We are way off that number. I know 2021, the COVID year was an exception where we hit 20%, which was never sustainable.

For our kind of a business with backward integration and now this formulation also ramping up, and at some point in time, the onco facility will also come into play, do you really think that 16% margin at an EBITDA level is a challenge even now?

Adhish Patil

No. With more regulated sales from our US FDA plant, with metformin getting US FDA approval, hoping that.

Then with the advent of formulation, the exports of formulation has already increased, and the EBITDA margins in the formulation business is now upwards of 16-17%, which is very good for us. It was consistent for the last two quarters.

With incoming oncology business, definitely, as the utilization goes up, we will start adding margins at the EBITDA level. Because as of now also, we are expensing some part of oncology developmental costs, some part in the P&L.

As the oncology sales improve, definitely the EBITDA margin should improve.

Sajal Kapoor

Just remind me again on the CapEx plan for this fiscal and the next fiscal, because I might have missed that.

Adhish Patil

Yeah. As of now, means greenfield project, we are not doing, but you can call it quasi greenfield, means mix between a brownfield and a greenfield.

Because the expansion, the new production lines, new production plants, which are putting up, are coming up mainly in the adjoining blocks of the existing facilities. Overall, the requirement of capital would be slightly low as compared to the greenfield projects, because in greenfield projects, plot development, the compound wall, your utility setups, your other admin setup, QC block setup, those take up a lot of funds.

Whereas in this kind of expansion what we are planning right now, and that overall plans are there in 3 to 4 places. We'll require a little lesser CapEx, but the asset turn of that CapEx should be slightly higher, because it is a quasi greenfield or brownfield, you can say.

This I was talking about the standalone. Plus in formulations also, we are coming up with additional block, because we already got EDQM block in formulation for OSD, I'm talking other than non-onco, and we want to double that capacity.

We want to make that block as EDQM as well. All put together, we feel that in next 2 to 3 years, at least 2 to 3 years, definitely around ₹300-400 crores of CapEx might go in.

Again, that will be a safe CapEx, more of increasing the existing capability rather than entering into all together new products. Whereas in formulation, the part of this CapEx will also go in formulation for developing our basket of oncology products, because that requires heavy CapEx.

Part of the CapEx will flow into the formulation business. We are expecting to grow our formulation business at least till 1,000 in next 3 to 5 years.

Sajal Kapoor

Right. How much of this expansion is backed by customer discussions and demand or order visibility versus we want to be ready with the capacity hoping that the demand will come?

Adhish Patil

Understood. Understood.

As far as the standalone business is concerned, because it is a brownfield or quasi greenfield kind of projects, all these products are the products which we are already working in. We have pretty good visibility of the demand of that product.

It is backed up by customer talks and discussion. As far as formulation is concerned, Vishwa, can you just explain how we are going forward for formulation demand?

Hello? Vishwa, are you on the line?

Operator

Mr. Savla, please go ahead.

Vishwa Savla

Honey, the voice is breaking for me a bit. Could you just repeat the last part?

I could not hear that very clearly.

Adhish Patil

Yeah. I will explain.

Vishwa, the question is that whatever CapEx we are doing in next 2 years or 3 years. As far as the formulation CapEx is concerned, how much of that CapEx is backed by the visibility of demand or customer discussions, and how much is more wishful, we will be ready with this and then probably the demand will come?

That is the question.

Vishwa Savla

Right. Just to break it down, CapEx is in two parts.

The capacity enhancement program that we're doing is pretty much based on our forecast for the signed products or where we have clear visibility on once our products are launched, we will need those kind of volumes. It's a brownfield expansion to meet our forecasted growth from existing products as well as new products.

As far as our CapEx on R&D development goes, those are typically, we look at developing products first, and then once the products are at late stage development, either dossiers are ready or near approval, that's when we start to sign contracts. Apart from a few contracts which are signed at a very early stage, most of them are signed once products are almost ready to be marketed.

Sajal Kapoor

Okay. That's helpful.

Thank you for answering all my questions, team. All the very best.

Thank you.

Vishwa Savla

Thank you.

Adhish Patil

Okay. Thanks.

Operator

Thank you. Next question comes from the line of Meghna Agarwal with Mount Intra.

Please go ahead.

Meghna Agarwal

Hello. Thank you for the opportunity.

Am I audible?

Operator

Ms. Agarwal, can you just speak a little more louder?

Meghna Agarwal

Yeah. Hello.

Hi. Am I audible?

Operator

Yes, please go ahead.

Meghna Agarwal

Yeah. Thank you for the opportunity.

Actually, can you just help me with the status of the salicylic acid? I was not able to catch it properly.

We are restarting the production. What happened actually?

Can you please explain?

Adhish Patil

Yeah. In salicylic acid, lot of improvements are to be made at the process level.

One was regarding the phenol recovery, which was going waste under mother liquor side. We already did trials few months back.

We have ordered the equipment as well. Before that equipment is installed, means it will be installed in any time now.

Before that is installed and we operate and check that it is working properly, though we have taken the pilot batches, ideally it should work properly. Once that is done, only then we feel that there is a scope for us to come in variable profit for salicylic acid.

Unless we install that equipment, there is no point in going ahead with higher production of salicylic acid because then that will, in turn, cause more losses for us. At the same time, in salicylic acid, what we have done, we have already commissioned, means it's almost in the late stage, we are going in for derivatives of salicylic acid.

Because the selling prices of derivatives of salicylic acid is much higher, the scope for margin expansion is more if we sell derivatives directly. Secondly, we are also going in for anti-dumping for salicylic acid.

Thirdly, there is one more scope of improvement in salicylic acid, and that is at the part of effluent. In China, what is happening, the effluent stream is just a saline water, high saline water, which they are allowed to drain into the sea because other impurities are not there in that.

We are checking the possibility with the government because if we have to evaporate all that thing, then that puts us little bit behind when it comes to competing with China. There are two, three challenges.

We are means tackling all of them together. One is your liquid-liquid extractor, what I was talking about, for improvement in phenol recovery.

Second was means reducing cost at the effluent side. Third is anti-dumping duty.

Fourth is your derivatives plant, which is means will come up by the May end or max by mid of June. There is a severe fabrication labor shortage what we observed in summer season, partly also because of lack of cooking gas and all.

The labor in the area are not there. That is why the plant got little delayed, but anyways, it will be done soon.

These are the multi-pronged approach what we are following up to improve the salicylic acid and then restart the facility.

Meghna Agarwal

Okay. Also just wanted to know any revenue guidance and EBITDA margin for FY '27, what are we expecting?

Adhish Patil

Yeah. We already did around 13% 13% more than little 13% EBITDA margins.

See, the war is one big challenge, how it will shape up, how far the crude prices will go up, whether they will stay up that high for a very long period of time, or they will stay around let's say, $90, $100, which is okay, which is fairly decent. There is slight uncertainty.

Hoping for the best, we would still like to target EBITDA margins anywhere between 13.5% to 14% for this FY '27. Had this war not been there, our earlier targets were definitely 14% to 14.5% EBITDA margins for FY '27.

Meghna Agarwal

Okay. Also one more last question.

I wanted to understand that what is happening in the antibiotic segment. Are we seeing any recovery or what is the thing going on the antibiotic segment, please?

Adhish Patil

There was some recovery on a sequential basis, means March versus December quarter. One thing which can hurt this antibiotic demand a bit more is the elevated prices of antibiotics, means of the raw materials and all.

If the crude remains too high, like more than $110, $120, then probably in short run, it might affect the domestic demand of antibiotics. That is what we feel.

Meghna Agarwal

Okay. As Aarti, are we seeing any volume growth or price growth in antibiotics?

How are we seeing for our company?

Adhish Patil

There is price growth right now. Means if we talk year-on-year, means in FY '27, we are expecting a very big price growth in antibiotics.

Volumes probably can be a bit flattish, because I'm saying flattish because anyways, the volumes of FY '26 were not that great for antibiotics, it won't go further down, is what we believe.

Meghna Agarwal

Sir. Thank you so much, and all the best.

Adhish Patil

Okay. Thank you.

Operator

Thank you. Next question comes from the line of Nilesh Ghuge with HDFC Securities.

Please go ahead. Mr.

Ghuge, please go ahead with the question. Mr.

Ghuge, please unmute yourself and go ahead with the question. Since there is no reply from the line of Mr.

Ghuge, we'll move to the next participant, and that is from the line of Rishabh Jain with Mody Capital. Please go ahead.

Rishabh Jain

Hello. Am I audible?

Operator

Yes. Yeah.

Rishabh Jain

Thank you for the opportunity. My question is, management indicated selective API price increase during the quarter.

Which products have witnessed price hikes, and how sustainable are these increase? Do we expect to see further increases?

Adhish Patil

Harit bhai, would you like to answer this question?

Harit Shah

No. Prices are now stable.

We are not expecting any further increase in the price. This will definitely depend on the raw material crude oil level prices basically.

All solvents and other chemicals are at peak level now, and we don't expect further going up unless crude goes beyond $140, $130, $140, but as

Rishabh Jain

Okay. Since you mentioned crude, are we seeing a crunch in any of the key raw materials right now because of war?

Is there any impact of the business?

Harit Shah

No, only in March we had some issue sourcing raw material, mainly ammonia, but otherwise raw material availability is not an issue as of now.

Rishabh Jain

Okay. Thank you.

That will be all from my side. Thank you.

Operator

Thank you. Next question comes from the line of Resham Jain with DSP Asset Managers.

Please go ahead.

Resham Jain

Hi. Good morning, sir.

I have three, three questions. First one is with respect to the overall CapEx, which you mentioned, ₹300 to ₹400 crores over the next three, four years.

Given that the cash generation is quite healthy and we always maintain some level of debt equity, is there any other CapEx which you're planning beyond this because then it will not match the overall cash generation over the next three, four years?

Adhish Patil

If at all we feel something is more lucrative, probably we might end up replacing some of the CapEx. If the current projects, the current two greenfield projects, the Saykha and the salicylic one, if there is stark improvement in the cash flow from these two projects, then probably we can have a bigger budgets as well, because then the cash generation would be a lot higher than what it is today.

Based on today's financials, this much is quite easily doable. As of today also, our consolidated long-term debt is around ₹328 crores, and short-term would be around ₹248 crores.

That way, and the debt-to-equity ratio is also historically lowest as of today in this quarter.

Resham Jain

That's right. That's why I asked.

Maybe by the end of the year, you may further basically fine-tune the overall CapEx budget.

Adhish Patil

Correct. That is absolutely correct.

Resham Jain

Okay. The second question is with respect to CWIP of ₹214 crores, which is currently sitting.

That is related to which project, sir?

Adhish Patil

How much? CWIP of what amount you said?

Resham Jain

₹214 crores, if I could see.

Adhish Patil

Yeah. Part of that was related to the cogen boiler and some brownfield expansions what we are doing, and also a major part of it is related to the formulation R&D, the dossiers, oncology dossiers, what we are developing.

That also requires a huge CapEx, and as and when we will get the approval, then we will start the amortization of those CapEx.

Resham Jain

Most of it should be capitalized this year, right? FY '27, maybe first half, except oncology?

Adhish Patil

Vishwa, can you give an fair idea about in oncology, how much we would, means the projects will go live this year and next year, means in terms of percentages? Adish,

Vishwa Savla

yeah, I think he's asking except oncology, but for a formulation part, the project lifecycles are quite long, most of the CWIP will start getting amortized over the next 24 months. There might be some portions that will be amortized this year and next year, but the major chunk would be post-24 months.

Resham Jain

Okay. Understood.

Sir, the last one. This year, all the projects which have started, like the methylamines and the salicylic acid and all, what will be the total EBITDA loss which is there in this year, because a lot of ramp-up related costs will be there?

Adhish Patil

For the entire year, you are asking FY '26?

Resham Jain

For the entire year, what is the total EBITDA loss because of new projects?

Adhish Patil

A very rough estimate, if you ask me, only the EBITDA loss would be somewhere in the range of ₹18 to ₹20 crores for the entire year.

Resham Jain

Understood. Sir.

Thank you. All the best.

Operator

Thank you.

Adhish Patil

Thank you.

Operator

Ladies and gentlemen, that was the last question for today. We have reached the end of question-and-answer session.

I now hand the conference over to the management for closing comments.

Adhish Patil

Thank you. Thank you for asking the questions and showing the interest in Aarti Drugs.

As utilization improves across our newly commissioned facilities and the benefits of our strategic investments starts reflecting more meaningfully in operations, we expect a gradual improvement in profitability and return ratios for the coming years. We remain committed to disciplined execution, operational excellence, and sustainable long-term value creation for all our stakeholders.

Thank you once again for your continued support and confidence in Aarti Drugs. For any further questions, please reach out to SGA, our Investor Relations Advisors.

Thank you, and have a nice day.

Operator

Thank you. On behalf of Aarti Drugs Limited, that concludes this conference.

Thank you for joining us. You may now disconnect your lines.